IBRX
NASDAQImmunityBio Inc.
Price$8.19+0.39 (+4.94%)
01:30 PM07:45 PM
News · 26 weeks490%
2026-03-012026-08-23
Mix2290d
- Insider11(50%)
- Other6(27%)
- SEC Filings4(18%)
- Leadership1(5%)
Latest news
25 items- PRImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice ChairmanDr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive Chairman ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leaders to support Dr. Soon-Shiong on strategy, partnerships, and initiatives intended to advance ImmunityBi
- SECSEC Form 10-Q filed by ImmunityBio Inc.10-Q - ImmunityBio, Inc. (0001326110) (Filer)
- SECImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 MillionQ2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®, driven by continued adoption among U.S. urologists and strong market access First-half 2026 net product revenue of $94.8 million, up 121% compared with the first-half of 2025 In July 2026, we announced the Emirates Drug Establishment of the United Arab Emirates granted the broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC for CIS and papillary disease and metastatic NSCLC The FDA accepted for review the Company’s supplemental Biologics License Appl
- SECImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung CancerThe UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full spectrum of BCG-unresponsive disease: carcinoma in situ (CIS) with or without papillary tumors, and papillary disease alone without CIS. The Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) granted Marketing Authorization for two ANKTIVA presentations, the broadest approval to date for ANKTIVA including papillary disease and CIS in non-muscle invasive bladder cancer and non-small cell lung cancer in patients who failed checkpoint inhibitors and chemotherapy.
- INSIDERDirector Cohen Cheryl sold $1,246,941 worth of shares (131,210 units at $9.50) as part of a pre-agreed trading plan and exercised 55,979 shares at a strike of $2.98, decreasing direct ownership by 37% to 125,386 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Selecky Christobel sold $1,439,066 worth of shares (159,478 units at $9.02) as part of a pre-agreed trading plan and exercised 159,478 shares at a strike of $2.99 (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Selecky Christobel exercised 96,722 shares at a strike of $2.94 and sold $871,216 worth of shares (96,722 units at $9.01) as part of a pre-agreed trading plan (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Simon Barry J. sold $196,908 worth of shares (25,000 units at $7.88) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 2,802,788 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Blaszyk Michael D4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Wendel Bruce4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Maxwell Linda4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Cohen Cheryl4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Clark Wesley4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Selecky Christobel4 - ImmunityBio, Inc. (0001326110) (Issuer)
- SECImmunityBio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- INSIDERDirector Simon Barry J. sold $165,306 worth of shares (23,033 units at $7.18) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 2,827,788 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- PRThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
- PRImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA® (nogapendekin alfa inbakicept-pmln), the company's IL-15 receptor agonist immunotherapy d
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- PRImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary disease FDA noted in its filing communication that the supplemental BLA accepted for review was based on the additional scientific data ImmunityBio provided at the Agency's request, detailing the overlapping features of papillary and CIS disease to determine adequate justification to allow for the expansion of the already approved indication of ANKTIVA with BCG to include the treatment of patients with BCG unresponsive NMIBC with papillary tumors During the FDA workshop held on May 18, 2026, panelists stated that CIS and papillary disease arise from the same cancer induci
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
- PRImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026NAI+BCG versus Nadofaragene Results: NAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene firadenovec-vncg in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary disease Median duration of CR with NAI+BCG was more than twice that observed with nadofaragene firadenovec-vncg (22.1 versus 9.7 months) NAI+BCG reduced cystectomy risk by 60% versus nadofaragene NAI+BCG versus TAR-200 Results: NAI+BCG demonstrated numerically higher 12-month CR rates and fewer treatment-related adverse events of any grade than TAR-200 (61.7% versus 83.5%) ImmunityBio
IBRX FAQ
7 questionsWhat does ImmunityBio Inc. do?
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer...Where does IBRX stock trade?
ImmunityBio Inc. (IBRX) is listed on NASDAQ.What sector and industry is IBRX in?
ImmunityBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ImmunityBio Inc. go public?
ImmunityBio Inc. (IBRX) completed its IPO in 2015.What are analysts saying about IBRX?
ImmunityBio Inc. has had 6 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1300.00 price target on 2026-03-12. Recent price targets range from $400.00 to $1300.00.What companies are similar to IBRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IBRX side-by-side with any of them on Quantisnow.How can I track IBRX on Quantisnow?
Quantisnow aggregates ImmunityBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBRX to receive live email and push alerts on every new disclosure.